AbbVie News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

22.05.18	AbbVie to Present at the Jefferies 2018 Global Healthcare Conference (PR Newswire)
16.05.18	AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual Meeting (PR Newswire)
13.05.18	Apon Wellbeing Ltd. wins MetLife Foundation Financial Innovation Competition powered by Verb, secures $50,000 Grant (PR Newswire)
08.05.18	AbbVie to Present at the UBS Global Healthcare Conference (PR Newswire)
02.05.18	AbbVie to Present at the 2018 Bank of America Merrill Lynch Health Care Conference (PR Newswire)
01.05.18	AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis (PR Newswire)
01.05.18	AbbVie Commences Self-Tender Offer for Up to $7.5 Billion of its Common Stock (PR Newswire)
30.04.18	AbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology (PR Newswire)
27.04.18	AbbVie Presents New Investigational Data For Elagolix (RTTNews)
26.04.18	AbbVie Reports First-Quarter 2018 Financial Results (PR Newswire)
25.04.18	AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis (PR Newswire)
25.04.18	AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients (PR Newswire)
24.04.18	Modern Miracles: America's 10 Best-Selling Drugs (RTTNews)
18.04.18	AbbVie to Present at the Deutsche Bank's 43rd Annual Health Care Conference (PR Newswire)
11.04.18	AGTC Awaits Gene Therapy Data, FDA Delays Decision On Elagolix, KPTI On Watch (RTTNews)
10.04.18	AbbVie : PDUFA Target Date Of Q3 For Elagolix In Endometriosis-Associated Pain (RTTNews)
10.04.18	ABBV's SELECT-COMPARE Hits Goals, MNLO's ATOMIK Flops, VTVT Down 63% After-Hrs (RTTNews)
09.04.18	Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis (PR Newswire)
06.04.18	AbbVie to Host First-Quarter 2018 Earnings Conference Call (PR Newswire)
05.04.18	Biogen, Samsung Bioepis Announce Deal With Abbvie For Imraldi Commercialization (RTTNews)
03.04.18	Will These Drugs Reach Blockbuster Status? (RTTNews)
28.03.18	Tom's of Maine New Whole Care® Mouthwash Provides Six Benefits in One (PR Newswire)
28.03.18	Biotech Stocks Facing FDA Decision In April (RTTNews)
23.03.18	ABBV Let Down By TRINITY, ODT Down 10% So Far This Month, NCNA On Watch (RTTNews)
22.03.18	AbbVie Announces Results from Phase 2 Study Evaluating Rovalpituzumab Tesirine (Rova-T) for Third-Line Treatment of Patients with DLL3-Expressing Relapsed/Refractory Small Cell Lung Cancer (PR Newswire)
21.03.18	AbbVie and the International Myeloma Foundation Announce Partnership to Study the Role of a Genetic Mutation in Outcomes of Patients with Multiple Myeloma (PR Newswire)
13.03.18	AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids (PR Newswire)
07.03.18	Zinbrynta Now Connected To Brain Inflammation (RTTNews)
02.03.18	Biogen, AbbVie Voluntarily Withdraw Worldwide MA For ZINBRYTA - Quick Facts (RTTNews)
26.02.18	AbbVie to Present at the Barclays Global Healthcare Conference (PR Newswire)
25.02.18	An Ear To The Pharma: 6 Stocks To Watch This Week (RTTNews)
22.02.18	AbbVie to Present at the Cowen and Company 38th Annual Health Care Conference (PR Newswire)
22.02.18	Les Néo-Écossais atteints de la maladie de Parkinson à un stade avancé bénéficient désormais du remboursement de DUODOPA® par le régime public d'assurance médicaments (PR Newswire)
22.02.18	Nova Scotians living with Advanced Parkinson's Disease now have public access to DUODOPA® to manage their disease (PR Newswire)
22.02.18	In The Spotlight: Inflarx (RTTNews)
21.02.18	AbbVie Reports Positive Topline Results From Phase 3 Elagolix Study (RTTNews)
21.02.18	Les Canadiens et les Canadiennes atteints d'hidradenite suppuree moderement a fortement evolutive commencent a beneficier du remboursement d'HUMIRA® (adalimumab) par le regime public d'assurance... (PR Newswire)
21.02.18	Canadians living with Moderate to Severe Hidradenitis Suppurativa are beginning to have public access to HUMIRA® (Adalimumab) to manage their disease (PR Newswire)
20.02.18	AbbVie and Voyager Therapeutics Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer's Disease and Other Tau-Related Neurodegenerative Diseases (PR Newswire)
17.02.18	AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting (PR Newswire)
17.02.18	AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting (PR Newswire)
16.02.18	AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn's Disease at 52 Weeks (PR Newswire)
15.02.18	AbbVie Increases Dividend and Announces New Stock Repurchase Program (PR Newswire)
12.02.18	AbbVie Showcases New, Late-Breaking Investigational Data at 2018 American Academy of Dermatology (AAD) Annual Meeting (PR Newswire)
06.02.18	AbbVie reçoit une recommandation favorable de la part du Comité canadien d'expertise sur les médicaments de l'ACMTS pour MAVIRET[MC], un médicament oral pour les patients atteints d'hépatite C (PR Newswire)
06.02.18	AbbVie receives a positive recommendation from the CADTH Canadian Drug Expert Committee for MAVIRET™ - an oral therapy for the treatment of patients with hepatitis C (PR Newswire)
26.01.18	AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results (PR Newswire)
12.01.18	AbbVie to Host Fourth-Quarter 2017 Earnings Conference Call (PR Newswire)
08.01.18	AbbVie's Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis (PR Newswire)
20.12.17	AbbVie's Upadacitinib Shows Positive Results as Monotherapy in Phase 3 Rheumatoid Arthritis Study, Meeting All Primary and Key Secondary Endpoints (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	28.46	2.63 %	K V
Swiss Life Hldg	712.60	1.86 %	K V
Part Grp Hldg	1’245.50	1.26 %	K V
Zurich Insur Gr	545.00	1.15 %	K V
Swiss Re	132.70	1.14 %	K V
Givaudan	3’945.00	-0.53 %	K V
Geberit	511.20	-0.66 %	K V
Alcon	76.38	-0.68 %	K V
Sika	212.90	-1.34 %	K V
CieFinRichemont	134.25	-2.65 %	K V

mehr

11.11.24		Börse New York in Grün: S&P 500 zum Handelsende freundlich
11.11.24		Optimismus in New York: S&P 500 am Nachmittag mit Kursplus
11.11.24		NYSE-Handel: S&P 500 mittags freundlich
11.11.24		Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen
02.07.24		Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge
02.07.24		Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten
06.05.24		S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude
26.04.24		Gewinne in New York: S&P 500 am Nachmittag fester